Beedan 50mg Tablet

Introduction

Beedan is a prescription medication that contains the active ingredient Dasatinib. It is available under the brand name Beedan. This medication is primarily used to treat certain types of cancer, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Uses

Beedan is prescribed for the treatment of chronic myeloid leukemia (CML) in adults and children, as well as Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults who have not responded to other treatments or have developed resistance.

Dosage and Administration

The dosage of Beedan may vary depending on the specific condition being treated and individual patient factors. Follow the instructions provided by your healthcare provider. Typically, the recommended dose is taken orally once daily, with or without food. Swallow the tablet whole with a glass of water, without crushing or chewing it.

Mechanism of Action

Beedan belongs to a class of medications called tyrosine kinase inhibitors. It works by inhibiting the activity of certain proteins, including BCR-ABL, which are responsible for the abnormal growth and survival of cancer cells. By blocking these proteins, Dasatinib helps to slow down or stop the growth of cancer cells, thereby treating the underlying condition.

Side Effects

Common side effects may include nausea, diarrhea, fatigue, headache, and rash. Note that not all patients will experience these side effects, and they may vary in severity. If you experience any severe or persistent side effects, contact your healthcare provider for further guidance.

Drug Interactions

Beedan may interact with certain other medications, including those that inhibit or induce the activity of certain liver enzymes. These interactions can affect the effectiveness or safety of the medication. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before taking Beedan, inform your healthcare provider about any medical conditions you have, including liver or kidney problems. This medication may not be suitable for everyone, and your healthcare provider will consider your individual medical history before prescribing it. Additionally, avoid grapefruit and grapefruit juice while taking Beedan, as it may increase the level of the medication in your blood.

Storage

Beedan should be stored at room temperature, away from moisture and heat. Keep it in its original packaging and out of reach of children. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Take the medication exactly as prescribed by your healthcare provider. Do not change the dosage or stop taking it without consulting them first.
• If you experience any side effects or have concerns about your treatment, don’t hesitate to reach out to your healthcare provider. They can provide guidance and support.
• Keep track of your medication schedule and set reminders if needed to ensure you take it consistently.
• It may be helpful to maintain a healthy lifestyle during treatment, including regular exercise, a balanced diet, and sufficient rest.
• Attend all scheduled appointments with your healthcare provider for monitoring and assessment of your condition.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Mastocytosis – Treatment (NHS UK) [Accessed 12 Jun. 2024] (online) Available at:
• Dasatinib 100 mg Film-coated Tablets (Health Professionals SmPC) Available at:
• Dasatinib (Drugs.com) [Accessed 8 Jun. 2024] (online) Available at:
• dasatinib tablet (RX) [Accessed 0 Jun. 2024] (online) Available at:
• Dasatinib (MedlinePlus) [Accessed 21 Jun. 2024] (online) Available at:
• Hořínková J, Šíma M, Slanař O. Pharmacokinetics of Dasatinib. Prague Med Rep. 2019;120(2-3):52-63. doi: 10.14712/23362936.2019.10. [Accessed 7 Jun. 2024] Available at: